Navigation Links
OrbusNeich Files Lawsuit Against Dr. Pavel Cervinka for Defamation
Date:3/21/2011

jailed diagonal branch, which are recognized risk factors for stent thrombosis. It also revealed discrepancies in the reported data and inconsistencies and misrepresentations in the study and the reporting of the study. Upon presentation of the findings of the independent evaluation, Dr. Cervinka admitted that he had made mistakes; however, changes which he made to subsequent presentations and the publication of the study in a medical Journal did not correct the reporting of the defects in the study, nor admit nor publish the errors and invalidity of the study.

Dr. Cervinka presented the results and conclusions of the study a number of times after he and the Masaryk Hospital were made aware of the defects in the study and the study reporting. As a result of the wide dissemination of the study and its erroneous conclusions that were not supported by the data, numerous clinicians stopped using the product and terminated clinical trials, and OrbusNeich suffered reputational damage.  Despite many requests by OrbusNeich, neither Dr. Cervinka nor the Masaryk Hospital has made public disclosure of the defects or deficiencies in this invalid study.

Alfred J. Novak, Chairman and Chief Executive Officer of OrbusNeich, said, "OrbusNeich stents and its other products provide innovative therapies that improve the lives of patients around the world.  We have taken this action only after many unsuccessful attempts to try to work with Dr. Cervinka and the Masaryk Hospital to correct the record.  We informed Dr. Cervinka and the Masaryk Hospital about the inaccuracies, misrepresentations and inconsistencies that were unveiled by an independent reviewer of the study, and they acknowledged our position. Nevertheless Dr. Cervinka and Masaryk Hospital continued to widely present and publish the flawed and invalid study, resulting in damages to OrbusNeich's business and reputation.  While we attempted to resolve this issue amicably, the actions by Dr. C
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OrbusNeich Announces Availability of Azule™ Cobalt Chromium Stent
2. Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeichs Genous™ Stent
3. Safety and Efficacy of OrbusNeichs Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
4. OrbusNeich Granted Expanded U.S. Patent of Genous™ Endothelial Progenitor Cell Capture Technology
5. OrbusNeichs Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents
6. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
7. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
8. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
9. OrbusNeichs Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease
10. 100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeichs Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient
11. Data Show OrbusNeichs Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)...  The Alabama Supreme Court, in a 6-3 decision on ... who mislead doctors into believing that prescription medicines the companies ... v. Wyeth, and the decision came after the Supreme Court ... year. Heninger Garrison Davis attorneys Lew Garrison and ... Danny Weeks . The decision won a ...
(Date:8/19/2014)... , Aug. 19, 2014 Research and ... "Pharmaceutical Contract Manufacturing - Global Strategic Business Report" ... analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in ... Vials, and IV solutions), Solid Dosage Forms (Tablets and ... Gels, Creams & Ointments). The report provides ...
(Date:8/19/2014)... 2014  AVIA – a provider-led accelerator that puts ... problems in healthcare ­– announces Sutter Health, a not-for-profit ... as the most recent addition to the AVIA Innovator ... AVIA,s inaugural cohort focused helping patients navigate the healthcare ... a patient,s providers so they work as a larger ...
Breaking Medicine Technology:Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 2Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 3Heninger Garrison Davis Clients To Get Their Day in Court Against Brand Drug Companies 4Global Pharmaceutical Contract Manufacturing - Strategic Business Report 2014 2AVIA and Sutter Health Join Forces to Address Healthcare's Most Pressing Challenges 2
... measurement technology, today announced the addition of the EmBand 24™ to the EmBand™ family of neuromarketing measurement devices. , ... , , ... ... ...
... , ATLANTA , March 22 Fulcrum Ventures announced today that they invested $1.25 ... solution for kit design, production, client supply management and patient specimen tracking.  Based in Columbus, Georgia , ... ... , ...
Cached Medicine Technology:EmSense Announces Release of Revolutionary EmBand 24(TM) 2EmSense Announces Release of Revolutionary EmBand 24(TM) 3EmSense Announces Release of Revolutionary EmBand 24(TM) 4Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC 2Fulcrum Ventures Leads $1.25 Million Investment in Path-Tec, LLC 3
(Date:8/20/2014)... Rockville Centre, NY (PRWEB) August 20, 2014 ... Martinotti and filed on August 7 in the multicounty ... New Jersey (IN RE DEPUY ASR HIP IMPLANTS LITIGATION; ... in the MCL have been dismissed without prejudice. The ... “in the process of being resolved.” The Rottenstein Law ...
(Date:8/20/2014)... It’s no secret that millions of Americans ... Institute on Drug Abuse, nearly 24 million Americans are ... alarming is the fact that the total number of ... locked in a struggle with substance abuse often feel ... the newly-redesigned AbuseTreatmentCenters.net has released updated lists of ...
(Date:8/20/2014)... One Call Alert expands its line of personal ... fully-mobile wearable device that connects customers to the help they ... a day, 365 days a year. , ResCube can go ... operates on the T-Mobile nationwide network like a cell phone, ... , Like with the other One Call Alert systems, ResCube ...
(Date:8/20/2014)... Auckland suggest that both major forms of diabetes are the ... today in the FASEB Journal (20 August), provide ... are both caused by the formation of toxic clumps of ... on 20 years, work in New Zealand, suggest that type-1 ... reversed by medicines that stop amylin forming these toxic clumps. ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
Breaking Medicine News(10 mins):Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 3Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2
... May 21, 2012. West Orange, NJ. Scientists at ... studies in multiple sclerosis at the Hilton San Diego ... John DeLuca, Nancy Chiaravalloti and Yael Goverover are addressing ... Multiple Sclerosis Centers (CMSC) and the Americas Committee for ...
... peers and primary care office staff can help patients improve ... new drug, a new study found. Barbara J. Turner, M.D., ... senior author. The randomized, controlled trial examined whether six ... care office staff could benefit African-American patients who had ...
... 21 (HealthDay News) -- Heart damage can be present in obese ... preliminary study found. Obesity is a risk factor for heart ... to their hearts. In the new study, researchers examined the ... overweight and 32 obese -- with no symptoms of heart disease. ...
... General Hospital (MGH) surgeons have developed a new technique ... In the May Annals of Otology, Rhinology ... which uses cryopreserved aortas from deceased donors to replace ... permanent tracheotomy and maintain voice and swallowing function with ...
... May 21 (HealthDay News) -- Having so-called intensivist physicians on ... death rates in ICUs that do not have similar coverage ... An intensivist is a doctor who specializes in the care ... or co-manage patients during the day are referred to as ...
... Almost a century after telephone pioneer Alexander Graham ... vapor sensors ― "electronic noses" ― are being developed ... and other futuristic uses. A new episode in ... series takes viewers on a behind-the-science tour of ...
Cached Medicine News:Health News:Kessler Foundation scientists present cognitive research findings at MS dual symposium 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 2Health News:Behavioral support from peers, staff lowers patients' blood pressure 3Health News:Obese Teens Can Have Heart Damage Without Showing Signs 2Health News:Donor aortic graft improves reconstruction after partial laryngectomy 2Health News:Night Staffing With Critical Care Docs May Lower ICU Death Rates 2